Cited by 178BRCA gene mutations in cancerBreast Lesions and CarcinomasGenetic Associations and Epidemiology

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CH EK 2 *1100delC Carriers

Open access

Schmidt, Marjanka K., Hogervorst, Frans, van Hien, Richard, Cornelissen, Sten, Broeks, Annegien, Adank, Muriel A., Meijers, Hanne, Waisfisz, Quinten, Hollestelle, Antoinette, Schutte, Mieke, van den Ouweland, Ans, Hooning, Maartje, Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Antoniou, Antonis C., Arndt, Volker, Bermisheva, Marina, Bogdanova, Natalia V., Bolla, Manjeet K., Brauch, Hiltrud, Brenner, Hermann, Brüning, Thomas, Burwinkel, Barbara, Chang-Claude, Jenny, Chenevix-Trench, Georgia, Couch, Fergus J., Cox, Angela, Cross, Simon S., Czene, Kamila, Dunning, Alison M., Fasching, Peter A., Figueroa, Jonine, Fletcher, Olivia, Flyger, Henrik, Galle, Eva, García-Closas, Montserrat, Giles, Graham G., Haeberle, Lothar, Hall, Per, Hillemanns, Peter, Hopper, John L., Jakubowska, Anna, John, Esther M., Jones, Michael, Khusnutdinova, Elza, Knight, Julia A., Kosma, Veli-Matti, Kristensen, Vessela, Lee, Andrew, Lindblom, Annika, Lubinski, Jan, Mannermaa, Arto, Margolin, Sara, Meindl, Alfons, Milne, Roger L., Muranen, Taru A., Newcomb, Polly A., Offit, Kenneth, Park-Simon, Tjoung-Won, Peto, Julian, Pharoah, Paul D.P., Robson, Mark, Rudolph, Anja, Sawyer, Elinor J., Schmutzler, Rita K., Seynaeve, Caroline, Soens, Julie, Southey, Melissa C., Spurdle, Amanda B., Surowy, Harald, Swerdlow, Anthony, Tollenaar, Rob A.E.M., Tomlinson, Ian, Trentham-Dietz, Amy, Vachon, Celine, Wang, Qin, Whittemore, Alice S., Ziogas, Argyrios, van der Kolk, Lizet, Nevanlinna, Heli, Dörk, Thilo, Bojesen, Stig, Easton, Douglas F.·2016·Journal of Clinical Oncology

DOI 10.1200/jco.2016.66.5844PMC PMC5019754

Open this paper in CoChat — free account

Abstract

Purpose: CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. Patients and Methods: CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies. Results: Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center–based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 × 10 −20 ). The OR was higher for estrogen receptor (ER)–positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 × 10 −21 ]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 × 10 −4 ). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom. Conclusion: These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2016.66.5844

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
Empirical Bayes Estimates of Age-Standardized Relative Risks for Use in Disease Mapping
Clayton, D. G., & Kaldor, J. M. (1987) · Biometrics · doi:10.2307/2532003 · Cited by 1,277
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Michailidou, K., kConFab Investigators, Australian Ovarian Cancer Study Group, The GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network, Hall, P. N., González‐Neira, A., Ghoussaini, M., Dennis, J., Milne, R. L., Schmidt, M. K., et al. (2013) · Nature Genetics · doi:10.1038/ng.2563 · Cited by 1,080
Self-citation
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M. D., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 947
Self-citation
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants
Mavaddat, N., Pharoah, P. D. P., Michailidou, K., Tyrer, J. P., Brook, M. N., Bolla, M. K., Wang, Q., Dennis, J., Dunning, A. M., Shah, M., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv036 · Cited by 562
Self-citation
CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies
* (2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 476
Self-citation
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., García‐Closas, M., Gescher, A. J., Key, T. J., Saxton, J., & Harvie, M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 349
Self-citation
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer, E. J., Verhoog, L., Brekelmans, C., Seynaeve, C., Tilanus-Linthorst, M., Wagner, A., Dukel, L., Devilee, P., van den Ouweland, A. V. D., van Geel, A. V., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02347-3 · Cited by 328
Self-citation

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 1

Adank M, 2015, Ned Tijdschr Geneeskd, 159, A8910

Sorted by citations

Items 101–178 of 178

Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway
Louro, J., Román, M., Moshina, N., Olstad, C. F., Larsen, M., Sagstad, S., Castells, X., & Hofvind, S. S. H. (2023) · Cancers · doi:10.3390/cancers15184517 · Cited by 6
“We did not include height, as a breast cancer risk factor, in addition to BMI as our model was attributed to the population of screened women, and not to women with genetic mutations, for whom the signiﬁcance of height was indicated [45,64,65].”
Background
Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse
Waha, A., Versmold, B., Kast, K., Kiechle, M. B., Ditsch, N. C., Meindl, A., Niederacher, D., Hahnen, E., Arnold, N., Mundhenke, C., et al. (2018) · TumorDiagnostik & Therapie · doi:10.1055/a-0574-4879 · Cited by 6
“[23] Schmidt MK, Hogervorst F, van Hien R et al.”
BackgroundInfluentialSelf-citation
Massive parallel sequencing in individuals with multiple primary tumours reveals the benefit of re-analysis
Wallander, K., Thonberg, H., Nilsson, D., & Tham, E. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-021-00203-z · Cited by 6
Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry
Dumont, M., Weber‐Lassalle, N., Joly-Beauparlant, C., Ernst, C., Droit, A., Feng, B., Dubois, S., Collin-Deschesnes, A. C., Soucy, P., Vallée, M., et al. (2022) · Cancers · doi:10.3390/cancers14143363 · Cited by 6
“A scoring system was established for the selection of families based on the assumption that rare, moderate-risk variants might be expected to confer a higher relative risk at young ages, as is the case for most known susceptibility genes [10].”
BackgroundMethodSelf-citation
Is prophylactic mastectomy justified in women without BRCA mutation?
Rutgers, E. J. T. (2019) · The Breast · doi:10.1016/s0960-9776(19)31126-9 · Cited by 6
Genetic predisposition to mosaic Y chromosome loss in blood is associated with genomic instability in other tissues and susceptibility to non-haematological cancersPreprint
Thompson, D. J., Genovese, G., Halvardson, J., Ulirsch, J. C., Wright, D. J., Terao, C., Davidsson, O. B., Day, F. R., Sulem, P., Jiang, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/514026 · Cited by 7
Self-citation
Genetic predisposition to mosaic Y chromosome loss in blood.
Thompson, D. J., Genovese, G., Halvardson, J., Ulirsch, J. C., Wright, D. J., Terao, C. C., Davidsson, O. B., Day, F. R., Sulem, P., Jiang, Y., et al. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.42407 · Cited by 5
Self-citation
Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H. R., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A., Lænkholm, A., Kruse, T. A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01655-y · Cited by 5
Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening
Glennon, K. I., Endo, M., Usui, Y., Iwasaki, Y., Breau, R. H., Kapoor, A., Lathrop, M. G., Tanguay, S., Momozawa, Y., & Riazalhosseini, Y. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00094 · Cited by 5
Breast Cancer Susceptibility—Towards Individualised Risk Prediction
Lakeman, I. M. M., Schmidt, M. K., van Asperen, C. J., & Devilee, P. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-00168-5 · Cited by 5
Self-citation
Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition – Mutation Types and their Biological and Clinical Relevance
Kleiblová, P., Stolařová, L., Křížová, K., Lhota, F., Hojný, J., Zemánková, P., Havránek, O., Vočka, M., Černá, M., Lhotová, K., et al. (2019) · Klinicka onkologie · doi:10.14735/amko2019s36 · Cited by 5
CHEK2-related breast cancer: real-world challenges
Weis, L. N., Bychkovsky, B., Hernandez, A. R., Barroso‐Sousa, R., & Sandoval, R. L. (2025) · Familial Cancer · doi:10.1007/s10689-025-00448-w · Cited by 4
Statistical methods for Mendelian models with multiple genes and cancers
Liang, J. W., Idos, G., Hong, C., Gruber, S. B., Parmigiani, G., & Braun, D. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22460 · Cited by 4
Germline mutations in the PALB2 and CHEK2 genes and hereditary cancer
Golotyuk, M. A., Berezhnoy, A. A., Kazantseva, N. V., Dorofeev, A., & Borzunova, T. I. (2023) · Ural Medical Journal · doi:10.52420/2071-5943-2023-22-3-126-136 · Cited by 4
Identification of Novel Metabolic Subtypes Using Multi-Trait Limited Mixed Regression in the Chinese Population
Ding, K., Zhou, Z., Ma, Y., Li, X., Xiao, H., Wu, Y., Wu, T., & Chen, D. (2022) · Biomedicines · doi:10.3390/biomedicines10123093 · Cited by 3
“Recent examples of proposed subtypes span diverse disease domains, including type 2 diabetes [3,27], breast cancer [28,29], asthma [30,31], autism [32,33], bipolar disorder, and schizophrenia [34,35].”
Background
Breast cancer: genetic personal risk factors: A review
Zolotykh, M. A., Bilyalov, A. I., Nesterova, A. I., Гимранов, А. М., Filina, Y. V., Rizvanov, A. A., & Рифкатовна, М. Р. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.2.202110 · Cited by 3
Pervasive genetic testing
Thiruchelvam, P. T. R., Fisher, C. S., Leff, D. R., & Domchek, S. M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30997-8 · Cited by 3
Ethnic Features of Genetic Susceptibility to Breast Cancer
Bermisheva, M., Bogdanova, N. V., Gilyazova, I. R., Zinnatullina, G., Бисултанова, З. И., & Хуснутдинова, Э. К. (2018) · Russian Journal of Genetics · doi:10.1134/s1022795418020047 · Cited by 4
Self-citation
Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
Welslau, M., Müller, V., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1811-6106 · Cited by 3
Self-citation
Managing Patient with Mutations in PALB2, CHEK2, or ATM
Francisco Acevedo, C., Deng, Z., Armengol, V. D., & Hughes, K. S. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0269-8 · Cited by 2
Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls
Zanti, M., Loizidou, M. A., O'Mahony, D. G., Dorling, L., Dennis, J., Devilee, P., Easton, D. F., Panayiotidis, M. I., Hadjisavvas, A., & Michailidou, K. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1248492 · Cited by 2
“Cumulative risks of breast cancer in the absence of other events were calculated by combining age-specific odds ratios with population incidence rates for Cyprus (2020) as a baseline, as previously described (Schmidt et al., 2016).”
MethodSelf-citation
Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care
Cheah, W., Cutress, R., Eccles, D., & Copson, E. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.08.006 · Cited by 2
Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2
Schreurs, M. A. C., Adank, M. A., Hollestelle, A., de Groot, R., Stommel-Jenner, D. J., van Asperen, C. J., Ausems, M. G. E. M., Berger, L. P. V., Blok, M. J., van Engelen, K., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086688 · Cited by 2
Self-citation
Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing
Reap, L. E., Ahsan, S., & Saleh, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.03.015 · Cited by 2
“One large caseecontrol study demonstrated increased risk for thyroid, prostate, colon, and renal cancer among individuals found to be CHEK2 positive.(19) Whether the presence of a CHEK2 mutation increases the risk of the development of early (younger than 35 years old) versus late onset breast cancer seems to be uncle…”
BackgroundMethod
Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer
McVeigh, U. M., McVeigh, T. P., Curran, C. E., Miller, N., Morris, D. W., & Kerin, M. J. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02174-x · Cited by 2
Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1036-0961 · Cited by 2
“[20] Schmidt MK, Hogervorst F, van Hien R et al.”
BackgroundSelf-citation
DNA methylation and breast cancer risk: value of twin and family studies
Li, S., Ye, Z., kConFab Investigators, Hopper, J. L., & Southey, M. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820951-6.00004-1 · Cited by 2
Self-citation
Panel Testing for Hereditary Breast Cancer: More or Less?
Landry, K. K., & Wood, M. E. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00361-4 · Cited by 1
Malignant fibroadenoma with CHEK2 mutation: a novel case
Ching, D., Pirasteh, S., Vora, B., Martin, R., & Gill, J. (2020) · Pathology · doi:10.1016/j.pathol.2020.04.009 · Cited by 1
The role of next‐generation sequencing in the examination of signaling genes in Brca1/2‐negative breast cancer cases
Çine, N., Ugurtas, C., Gökbayrak, M. E., Aydın, D., Demir, G., Kuru, S., Akkoyunlu, D. S., KESKİN, S. E., Şimşek, T., Çabuk, D., et al. (2022) · Annals of Human Genetics · doi:10.1111/ahg.12488 · Cited by 1
Moderate-Penetrance Predisposition to Breast Cancer
Robson, M. E. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0289-4 · Cited by 1
Self-citation
Breast Cancer with Hereditary Cancer Predisposition Syndromes
Rao, R., Mauer, C. B., Chen-Seetoo, M., & Peng, Y. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-16518-5_8 · Cited by 1
Genetic Predictors of Malignancy: a Literature Review
Пушкарев, А. В., Галеев, М. Г., Пушкарев, В. А., & Султанбаев, А. В. (2021) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2021-11-2-157-165 · Cited by 1
Hereditary Cancer Counseling and Germline Genetic Testing
Menendez, C. S., Marcom, P. K., & Sutton, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-75377-1_20 · Cited by 1
Statistical approaches for meta‐analysis of genetic mutation prevalence
Hujoel, M. L. A., Parmigiani, G., & Braun, D. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22364 · Cited by 1
“Beyond the challenge of rare mutations, the second challenge is that large population‐based studies are not feasible in every ethnic group and the prevalence of genetic mutations can differ greatly depending on the population (Schmidt et al., 2016).”
Background
NGS zur Selektion innovativer Therapien – Was bringt das?
Schulmeyer, C. E., Bader, S., Hübner, H., Rübner, M., & Fasching, P. A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04774-9 · Cited by 1
Self-citation
2. Wissenschaftspreis: Verbesserung der Risikokalkulation für Brustkrebs durch polygenen Risikoscore
Borde, J., Ernst, C., Hahnen, E., & Schmutzler, R. K. (2021) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1376-3533 · Cited by 1
“Cancer Med 2018; 7: 1349–1358 [3] Schmidt MK, Hogervorst F, van Hien R et al.”
BackgroundSelf-citation
Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer riskPreprint
Wilcox, N., Dumont, M., González‐Neira, A., Carvalho, S., Beauparlant, C. J., Crotti, M., Luccarini, C., Soucy, P., Dubois, S., Núñez‐Torres, R., et al. (2022) · medRxiv · doi:10.1101/2022.06.17.22276537 · Cited by 1
Self-citation
Management of the Patient with a Genetic Predisposition for Breast Cancer
Colonna, S. V., & Gammon, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_31
Hereditäre Tumordiagnostik – Mammakarzinom: BRCA1, BRCA2 und derzeitiger Stand der Multigenanalysen
Hahnen, E., Wappenschmidt, B., Rhiem, K., & Schmutzler, R. K. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0042-122159
“[40] Schmidt MK, Hogervorst F, van Hien R et al.”
Self-citation
Mammakarzinom: BRCA1, BRCA2 und derzeitiger Stand der Multigenanalysen
Hahnen, E., Waha, A., Wappenschmidt, B., Rhiem, K., & Schmutzler, R. K. (2017) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/s-0043-105663
“JAMA oncology 2015; 1 (1): 23–32 [40] Schmidt MK, Hogervorst F, van Hien R et al.”
Self-citation
Mutations in CHEK2 and risk of gastric cancer: a case-control study
Lv, Z.-C., Liu, R., Mu, L., Ma, J., & Yang, L. (2017) · Biomedical Research-tokyo
Früherkennung von Karzinomen
Witzel, I., & Speiser, D. (2018) · Der Gynäkologe · doi:10.1007/s00129-018-4203-y
Früherkennung von Mammakarzinomen
Witzel, I., & Speiser, D. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-4024-9
Update Mammakarzinom 2018 (Teil 2) – Fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention
Schneeweiß, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., et al. (2018) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/s-0043-124850
Self-citation
Prophylactic Mastectomy in Patients with Atypical Breast Lesions
Boughey, J. C., & Degnim, A. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92657-5_11
Editorial: Accomplishments, Collaborative Projects and Future Initiatives in Breast Cancer Genetic Predisposition
Peterlongo, P., & Carvajal‐Carmona, L. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00841
“The moderate-penetrance genes ATM and CHEK2 are also associated with breast cancer, conferring a 20% average lifetime risk (3, 4).”
Background
Comprehensive analysis and ACMG-based classification of CHEK2 variants in Spanish hereditary cancer patientsPreprint
Vargas‐Parra, G., Valle, J. D., Rofes, P., Gausachs, M., Stradella, A., Moreno-Cabrera, J. M., Velasco, À., Tornero, E., Menéndez, M., Muñoz, X., et al. (2020) · doi:10.22541/au.159050458.86704879
Genetische Grundlagen des erblichen Mamma- und Ovarialkarzinoms
Hahnen, E., & Meindl, A. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04696-y
Self-citation
PanelPRO: a general framework for multi-gene, multi-cancer Mendelian risk prediction modelsPreprint
Liang, J. W., Idos, G., Hong, C., Gruber, S. B., Parmigiani, G., & Braun, D. (2021) · arXiv (Cornell University)
Implicaciones quirúrgicas de paneles multigénicos durante el tratamiento quimioterápico neoadyuvante en mujeres de alto riesgo con cáncer de mama
Escudero, L. S., Garcés, M. Y. R., & Ruiz, F. J. J. (2022) · Cirugía Española · doi:10.1016/j.ciresp.2022.03.014
Update Mammakarzinom 2021 Teil 4 – Prävention und frühe Krankheitsstadien
Thomssen, C., Fehm, T. N., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Lüftner, D., Müller, V., Schütz, F., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1816-1625
Self-citation
A framework evaluating the utility of multi-gene, multi-disease population-based panel testing that accounts for uncertainty in penetrance estimatesPreprint
Liang, J. W., Christensen, K. D., Green, R. C., & Kraft, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.10.503415
Surgical implications of multigenic testing during neoadjuvant chemotherapy treatment in high-risk women with breast cancer
Escudero, L. S., Garcés, M. Y. R., & Ruiz, F. J. J. (2022) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2022.03.021
Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien
Welslau, M., Müller, V., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1898-4367
“[18] Schmidt MK, Hogervorst F, van Hien R et al.”
BackgroundSelf-citation
Prävention des Mamma- und Ovarialkarzinoms bei Frauen mit Genmutationen
Tüchler, A., Hahnen, E., Schmutzler, R., & Rhiem, K. (2023) · Die Gynäkologie · doi:10.1007/s00129-023-05163-0
Self-citation
Familiärer Brust- und Eierstockkrebs – Prävention und Therapie
Rhiem, K., Tüchler, A., Schmutzler, R. K., & Hahnen, E. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05222-0
Self-citation
Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimates
Liang, J. W., Christensen, K. D., Green, R. C., & Kraft, P. (2024) · npj Genomic Medicine · doi:10.1038/s41525-024-00414-y
Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequenced dataPreprint
Mukhtar, T. K., Wilcox, N., Dennis, J., Yang, X., Naven, M., Mavaddat, N., Perry, J. R. B., Gardner, E. J., & Easton, D. F. (2024) · medRxiv · doi:10.1101/2024.07.01.24309756
Self-citation
Hereditary Cancers
Sarin, R. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_74
Reduced Breast and Ovarian Cancer Through Targeted Genetic Testing: Estimates Using the NEEMO Microsimulation Model
Petelin, L., Cunich, M. M., Procopio, P., SCHOFIELD, D. J., Devereux, L., Nickson, C., James, P. A., Campbell, I., & Trainer, A. H. (2024) · Cancers · doi:10.3390/cancers16244165
Additional file 3 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597108
Additional file 7 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597120
Additional file 5 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597114
Additional file 2 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597105
Additional file 9 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597126
Additional file 2 of Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
Smid, M., Schmidt, M. K., der Smissen, W. J. C. P., Ruigrok-Ritstier, K., Schreurs, M. A. C., Cornelissen, S., Garcia, A. M., Broeks, A., Timmermans, A. M., Trapman-Jansen, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22792719
Self-citation
Additional file 4 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597111
Additional file 1 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597102
Additional file 4 of Massive parallel sequencing in individuals with multiple primary tumours reveals the benefit of re-analysis
Wallander, K., Thonberg, H., Nilsson, D., & Tham, E. (2021) · Figshare · doi:10.6084/m9.figshare.16900764
Additional file 8 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597123
Additional file 6 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597117
Additional file 10 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597129
Risk-Reducing Mastectomy in BRCA1/2 and Other High-Risk Gene Carriers: Current Evidence and Practical Guidance
Lee, J. H., Ryu, J. M., Park, J. S., Kim, J. H., Cha, C., Eoh, K. J., Yang, Y., Lee, B.-Y., Han, S.-A., & Kim, S.-W. (2026) · Journal of Breast Cancer · doi:10.4048/jbc.2025.0279
“For moderate-penetrance genes, including CHEK2 [28-30], ATM [5,6,31,32], MRI-based surveillance is usually preferred over prophylactic surgery, with RRM reserved for additional modifiers (e.g., a strong family history and prior chest irradiation).”
Later age of natural menopause among women with the pathogenic CHEK2 c.1100delC variant: a validation study
Schreurs, M. A. C., Hollestelle, A., Adank, M. A., Louwers, Y. V., van Asperen, C. J., Ausems, M. G. E. M., van de Beek, I., Collee, M. J., Dommering, C. J., Gómez-García, E. B., et al. (2026) · Journal of Medical Genetics · doi:10.1136/jmg-2025-111339
“17 21 29–31 Therefore, it is unclear whether the longer oestrogen exposure should be considered as an important breast cancer risk factor in CHEK2 c.1100delC heterozygotes.”
Self-citation
The contribution of rare germline variants to the immune landscape of breast cancer
Rojas-Rodríguez, F., Canisius, S., Keeman, R., Bernstein, A. J., Hurson, A. N., Ahearn, T. U., Andrulis, I. L., Antoniou, A. C., Behrens, S., Białkowska, K., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01662-6
Self-citation
Germline Pathogenic Variants in Breast Cancer–Predisposing Genes Among Early-Onset Female and Male Breast Cancer in Ethiopia
Hjelm, T. E., Gebremariam, T. Y., Weldearegay, M. F., Ayele, B. G., Assefa, M., Anberber, E., Kvist, A., Törngren, T., Borg, Å., Margolin, S., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00699
Self-citation
Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn’t Just Ductal
Beck, A. C., Carroll, E. F., Mukhtar, R. A., Cassidy, M. R., Flanagan, M. R., Gamble, L. A., & Erdahl, L. M. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20368-y

Authors: Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., Meijers, H., Waisfisz, Q., Hollestelle, A., Schutte, M., van den Ouweland, A., Hooning, M., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Antoniou, A. C., Arndt, V., Bermisheva, M., Bogdanova, N. V., Bolla, M. K., Brauch, H., Brenner, H., Brüning, T., Burwinkel, B., Chang-Claude, J., Chenevix-Trench, G., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Dunning, A. M., Fasching, P. A., Figueroa, J., Fletcher, O., Flyger, H., Galle, E., García-Closas, M., Giles, G. G., Haeberle, L., Hall, P., Hillemanns, P., Hopper, J. L., Jakubowska, A., John, E. M., Jones, M., Khusnutdinova, E., Knight, J. A., Kosma, V.-M., Kristensen, V., Lee, A., Lindblom, A., Lubinski, J., Mannermaa, A., Margolin, S., Meindl, A., Milne, R. L., Muranen, T. A., Newcomb, P. A., Offit, K., Park-Simon, T.-W., Peto, J., Pharoah, P. D. P., Robson, M., Rudolph, A., Sawyer, E. J., Schmutzler, R. K., Seynaeve, C., Soens, J., Southey, M. C., Spurdle, A. B., Surowy, H., Swerdlow, A., Tollenaar, R. A. E. M., Tomlinson, I., Trentham-Dietz, A., Vachon, C., Wang, Q., Whittemore, A. S., Ziogas, A., van der Kolk, L., Nevanlinna, H., Dörk, T., Bojesen, S., & Easton, D. F.
Affiliations: F. Hoffmann-La Roche AG (CH)
Marjanka K. Schmidt, Frans Hogervorst, Richard van Hien, Sten Cornelissen, Annegien Broeks, and Lizet van der Kolk, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital; Muriel A. Adank, Hanne Meijers, and Quinten Waisfisz, VU University Medical Center, Amsterdam; Antoinette Hollestelle, Mieke Schutte, Maartje Hooning, and Caroline Seynaeve, Erasmus MC Cancer Institute; Ans van den Ouweland, Erasmus University Medical Center, Rotterdam; Rob A.E.M. Tollenaar, Leiden University Medical Center,...
Corresponding author: Schmidt, Marjanka K.
ORCID: Schmidt, Marjanka K.
Cornelissen, Sten
Broeks, Annegien
Adank, Muriel A.
Waisfisz, Quinten
Hollestelle, Antoinette
Hooning, Maartje
Andrulis, Irene L.
Antoniou, Antonis C.
Arndt, Volker
Bermisheva, Marina
Bogdanova, Natalia V.
Bolla, Manjeet K.
Brauch, Hiltrud
Brenner, Hermann
Brüning, Thomas
Burwinkel, Barbara
Chang-Claude, Jenny
Couch, Fergus J.
Cox, Angela
Cross, Simon S.
Czene, Kamila
Dunning, Alison M.
Fasching, Peter A.
Figueroa, Jonine
Fletcher, Olivia
Galle, Eva
Giles, Graham G.
Hall, Per
Hillemanns, Peter
Hopper, John L.
Jakubowska, Anna
John, Esther M.
Knight, Julia A.
Kosma, Veli-Matti
Kristensen, Vessela
Lindblom, Annika
Margolin, Sara
Milne, Roger L.
Muranen, Taru A.
Newcomb, Polly A.
Pharoah, Paul D.P.
Robson, Mark
Rudolph, Anja
Sawyer, Elinor J.
Southey, Melissa C.
Spurdle, Amanda B.
Surowy, Harald
Swerdlow, Anthony
Tollenaar, Rob A.E.M.
Tomlinson, Ian
Vachon, Celine
Wang, Qin
Whittemore, Alice S.
Ziogas, Argyrios
Nevanlinna, Heli
Dörk, Thilo
Bojesen, Stig
Easton, Douglas F.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2016-08-10
Volume: 34
Issue: 23
Pages: 2750-2760
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2016.66.5844
PMC: PMC5019754
OpenAlex: W2400927555
Cited by: 173
References: 27
Citations by year: 2026: 5 · 2025: 1 · 2024: 16 · 2023: 17 · 2022: 30 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 22 · 2017: 14 · 2016: 3
FWCI: 17.59
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Research Portal (King's College London) (submittedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Apollo (University of Cambridge) (submittedVersion)
Apollo
Funders: U.S. Department of Health and Human Services
Susan G. Komen for the Cure (CA116201, 39346, DDHK 2009-4318, 70492, 193387/V50, C1287/A10118, 01KW9976/8, DDHK 2004-3124, HEALTH-F2-2009-223175, CA92044, LVS39420, 01KW9975/5, 2007-3839, CA58860, 01KW9977/0, 2009 4363, 193387/H10, BBMRI-NL CP16, RUS08/017, 209057, 110837, 01KW0114, RUL 1997-1505, PBZ_KBN_122/P05/2004, UM1 CA164920, C490/A10124)
Mayo Clinic (CA116201)
Breast Cancer Research Foundation (UM1 CA164920, C490/A10124, 2007-3839, 39346, 01KW0114, 70492, 01KW9977/0, DDHK 2009-4318, C1287/A10118, CA116201, 01KW9976/8, RUL 1997-1505, CA92044, 209057, 110837, RUS08/017, BBMRI-NL CP16, CA58860, 2009 4363, LVS39420, 01KW9975/5, 193387/V50, 193387/H10, PBZ_KBN_122/P05/2004, HEALTH-F2-2009-223175, DDHK 2004-3124)
Memorial Sloan-Kettering Cancer Center
Itä-Suomen Yliopisto (RUL 1997-1505, 110837, DDHK 2009-4318, CA92044, LVS39420, 70492, 2007-3839, 193387/V50, C1287/A10118, PBZ_KBN_122/P05/2004, RUS08/017, C490/A10124, 193387/H10, 01KW9977/0, CA116201, 39346, 209057, 2009 4363, UM1 CA164920, HEALTH-F2-2009-223175, BBMRI-NL CP16, 01KW9976/8, 01KW9975/5, CA58860, DDHK 2004-3124, 01KW0114)
Helsingin Yliopisto
Helsingin ja Uudenmaan Sairaanhoitopiiri
Sundhed og Sygdom, Det Frie Forskningsråd (C1287/A10118, DDHK 2009-4318, 39346, PBZ_KBN_122/P05/2004, CA116201, HEALTH-F2-2009-223175, 01KW9977/0, CA92044, UM1 CA164920, 01KW9975/5, LVS39420, CA58860, RUS08/017, 70492, C490/A10124, 01KW0114, 2007-3839, 193387/H10, 01KW9976/8, 209057, 2009 4363, BBMRI-NL CP16, 193387/V50, DDHK 2004-3124, 110837, RUL 1997-1505)
Deutsches Krebsforschungszentrum (PBZ_KBN_122/P05/2004, 110837, 01KW9976/8, DDHK 2004-3124, UM1 CA164920, 01KW9977/0, 01KW0114, RUS08/017, 193387/H10, C490/A10124, 2009 4363, 70492, 193387/V50, C1287/A10118, CA116201, 2007-3839, CA92044, HEALTH-F2-2009-223175, LVS39420, BBMRI-NL CP16, CA58860, 209057, DDHK 2009-4318, 01KW9975/5, RUL 1997-1505, 39346)
Kreftforeningen (BBMRI-NL CP16, PBZ_KBN_122/P05/2004, UM1 CA164920, RUL 1997-1505, 70492, DDHK 2009-4318, HEALTH-F2-2009-223175, 2009 4363, 2007-3839, C1287/A10118, 193387/V50, DDHK 2004-3124, 39346, CA58860, 01KW9975/5, 209057, RUS08/017, 193387/H10, C490/A10124, 01KW0114, 110837, 01KW9976/8, LVS39420, CA116201, CA92044, 01KW9977/0)
London School of Hygiene and Tropical Medicine
David F. and Margaret T. Grohne Family Foundation (01KW9977/0, CA92044, 01KW9975/5, 2009 4363, PBZ_KBN_122/P05/2004, UM1 CA164920, BBMRI-NL CP16, CA58860, C1287/A10118, 70492, CA116201, DDHK 2009-4318, C490/A10124, 110837, DDHK 2004-3124, 209057, HEALTH-F2-2009-223175, 2007-3839, 193387/V50, RUL 1997-1505, 193387/H10, 01KW0114, 39346, 01KW9976/8, RUS08/017, LVS39420)
Wellcome Trust (090532, 090532/Z/09/Z)
Francis Crick Institute (10124, 10119)
QIMR Berghofer Medical Research Institute
Lon V. Smith Foundation (01KW0114, LVS39420, 70492, RUS08/017, 01KW9975/5, DDHK 2009-4318, C490/A10124, 209057, CA116201, PBZ_KBN_122/P05/2004, UM1 CA164920, 2007-3839, 01KW9976/8, 01KW9977/0, C1287/A10118, BBMRI-NL CP16, 110837, CA92044, HEALTH-F2-2009-223175, CA58860, RUL 1997-1505, DDHK 2004-3124, 2009 4363, 39346, 193387/H10, 193387/V50)
Cancer Research UK (LVS39420, 223175, 11174, 70492, 10119, 01KW9977/0, C1287/A10118, C1287/A12014, RUS08/017, C1287‐A10118, 12014, HEALTHF2-2009-223175, 16561, 01KW9975/5, 16565, RUL 1997-1505, 209057, C1287/ A12014, 110837, C1287, CA92044, PBZ_KBN_122/P05/2004, 20861, 2007-3839, 01KW9976/8, 193387/V50, 10118, CA116201, 10124, 2009 4363, DDHK 2004-3124, C490/A10124, UM1 CA164920, 39346, 01KW0114, CA58860, 193387/H10, BBMRI-NL CP16, DDHK 2009-4318)
National Institute for Health and Care Research (110837, 39346, RUS08/017, 193387/V50, 01KW9976/8, HEALTH-F2-2009-223175, 03/DHCS/03/G121/51, DDHK 2009-4318, PBZ_KBN_122/P05/2004, 209057, CA116201, CA92044, C1287/A10118, 01KW9975/5, BBMRI-NL CP16, 01KW9977/0, RUL 1997-1505, 70492, UM1 CA164920, LVS39420, DDHK 2004-3124, 2009 4363, 01KW0114, CA58860, 2007-3839, C490/A10124, 193387/H10)
King's College London
University of Oxford
National Breast Cancer Foundation (01KW9975/5, LVS39420, 2009 4363, HEALTH-F2-2009-223175, BBMRI-NL CP16, 39346, CA116201, RUS08/017, 193387/H10, 110837, CA58860, DDHK 2009-4318, DDHK 2004-3124, 2007-3839, 01KW9977/0, 193387/V50, 01KW9976/8, C490/A10124, RUL 1997-1505, 70492, CA92044, 01KW0114, 209057, UM1 CA164920, C1287/A10118, PBZ_KBN_122/P05/2004)
Agency for Science, Technology and Research
Robert Bosch Stiftung (01KW9976/8, 193387/H10, 01KW0114, DDHK 2009-4318, DDHK 2004-3124, C1287/A10118, UM1 CA164920, 70492, BBMRI-NL CP16, RUS08/017, CA116201, CA92044, HEALTH-F2-2009-223175, 01KW9977/0, 01KW9975/5, 193387/V50, 2009 4363, C490/A10124, 39346, PBZ_KBN_122/P05/2004, 110837, RUL 1997-1505, CA58860, 2007-3839, 209057, LVS39420)
Universität Heidelberg
Universiteit Leiden
University of Melbourne
Universiteit van Amsterdam
Vrije Universiteit Amsterdam
Eberhard Karls Universität Tübingen
Bundesministerium für Bildung und Forschung (193387/V50, 2007-3839, 70492, BBMRI-NL CP16, 01KW9977/0, 39346, 01KW9975/5, 01KW9976/8, 2009 4363, C1287/A10118, C490/A10124, HEALTH-F2-2009-223175, 01KW0114, PBZ_KBN_122/P05/2004, RUS08/017, 110837, CA92044, CA58860, DDHK 2009-4318, CA116201, UM1 CA164920, 193387/H10, RUL 1997-1505, 209057, LVS39420, DDHK 2004-3124)
Cancerfonden
Gentofte Hospital
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184021007, NWO 184.021.007)
Deutsche Gesetzliche Unfallversicherung
Herlev Hospital
University of Toronto
Karolinska Institutet (DDHK 2004-3124, 01KW9977/0, 39346, C1287/A10118, CA58860, HEALTH-F2-2009-223175, DDHK 2009-4318, LVS39420, CA116201, PBZ_KBN_122/P05/2004, RUL 1997-1505, RUS08/017, 2009 4363, C490/A10124, CA92044, 01KW9975/5, 01KW0114, 193387/H10, UM1 CA164920, BBMRI-NL CP16, 193387/V50, 110837, 70492, 01KW9976/8, 2007-3839, 209057)
Kuopion Yliopistollinen Sairaala
Stockholms Läns Landsting
KWF Kankerbestrijding (193387/V50, NKI 2007–3839; 2009 4363, PBZ_KBN_122/P05/2004, DDHK 2004‐3124, 2007-3839, 2004-3124, LVS39420, RUS08/017, 01KW9976/8, UM1 CA164920, 70492, 1997-1505, HEALTH-F2-2009-223175, C490/A10124, 2009 4363, 01KW9977/0, CA116201, 193387/H10, NKI 2007–3839, DDHK 2009‐4318, CA58860, RUL1997-1505, CA92044, 01KW0114, 39346, 209057, 110837, C1287/A10118, 01KW9975/5, BBMRI-NL CP16)
Leids Universitair Medisch Centrum
Universitetet i Oslo (209057)
Norges Forskningsråd (01KW0114, 209057, BBMRI-NL CP16, 193387/H10, 2007-3839, C1287/A10118, 01KW9975/5, 110837, 2009 4363, RUL 1997-1505, 01KW9976/8, CA58860, PBZ_KBN_122/P05/2004, DDHK 2004-3124, CA116201, UM1 CA164920, C490/A10124, LVS39420, 39346, 193387/V50, 01KW9977/0, RUS08/017, HEALTH-F2-2009-223175, CA92044, DDHK 2009-4318, 70492)
Medizinischen Hochschule Hannover (01KW0114, 2007-3839, 39346, 2009 4363, DDHK 2004-3124, 209057, 193387/H10, C1287/A10118, 01KW9976/8, 01KW9975/5, 193387/V50, 110837, RUL 1997-1505, RUS08/017, C490/A10124, BBMRI-NL CP16, CA92044, CA58860, DDHK 2009-4318, CA116201, LVS39420, 70492, HEALTH-F2-2009-223175, PBZ_KBN_122/P05/2004, 01KW9977/0, UM1 CA164920)
Technische Universität München
Deutsche Krebshilfe (HEALTH-F2-2009-223175, 193387/H10, (#110837, 2007-3839, 01KW0114, DDHK 2004-3124, CA58860, RUL 1997-1505, UM1 CA164920, 01KW9976/8, C490/A10124, DDHK 2009-4318, CA92044, 209057, PBZ_KBN_122/P05/2004, 01KW9977/0, BBMRI-NL CP16, 01KW9975/5, 39346, CA116201, 2009 4363, C1287/A10118, 70492, 193387/V50, LVS39420, RUS08/017)
Universität zu Köln
Pomorski Uniwersytet Medyczny W Szczecinie
Universitätsklinikum Köln
National Institutes of Health (LVS39420, CA11620 1, DDHK 2009-4318, 01KW0114, 01KW9977/0, 01KW9975/5, 223175, 39346, 184.021.007, 193387/V50, 2007-3839, RUL 1997-1505, 193387/H10, 110837, 70492, C490/A10124, PBZ_KBN_122/P05/2004, RUS08/017, 01KW9976/8, C1287/A10118, BBMRI-NL CP16, 209057, HEALTH-F2-2009-223175, 3u01ca164920-07s1, DDHK 2004-3124, 2009 4363, CA116167, CA164920, CA58860)
School of Medicine, Stanford University
U.S. Army (DAMD17-01-1-0729)
University of California, Los Angeles
University of California, Irvine
Medical Research Council (110837, CA58860, 70492, CA116201, PBZ_KBN_122/P05/2004, RUL 1997-1505, DDHK 2004-3124, RUS08/017, MC_PC_14105, BBMRI-NL CP16, HEALTH-F2-2009-223175, UM1 CA164920, 01KW9975/5, 01KW9976/8, 193387/V50, 01KW0114, 193387/H10, 2009 4363, 2007-3839, C490/A10124, C1287/A10118, CA92044, 39346, 209057, LVS39420, 01KW9977/0, DDHK 2009-4318)
National Health and Medical Research Council (251553, 199600, 400281, 209057, 400413, 400281, 400413, 504711)
Cancer Council South Australia
Cancer Council Victoria (DDHK 2004-3124, UM1 CA164920, 110837, C1287/A10118, CA92044, 39346, 209057, HEALTH-F2-2009-223175, 2007-3839, CA116201, 193387/V50, 01KW9976/8, 01KW0114, DDHK 2009-4318, C490/A10124, PBZ_KBN_122/P05/2004, CA58860, 2009 4363, RUS08/017, RUL 1997-1505, BBMRI-NL CP16, 01KW9977/0, 01KW9975/5, 70492, LVS39420, 193387/H10)
Cancer Council NSW
Cancer Council Tasmania
Russian Academy of Sciences
Erasmus Universitair Medisch Centrum Rotterdam
Universitätsklinikum Hamburg-Eppendorf
National Cancer Institute (01KW9976/8, RUS08/017, PBZ_KBN_122/P05/2004, U01CA058860, HEALTH-F2-2009-223175, CA116167, DDHK 2009-4318, R01CA058860, 01KW9975/5, R01CA116167, UM1CA164920, 193387/H10, R01CA069664, R01CA047305, RUL 1997-1505, CA-116201, 2009 4363, R01CA192393, 209057, CA164920, CA58860, 01KW9977/0, 2007-3839, 193387/V50, 39346, CA176785, 01KW0114, K07CA092044, CA192393, C1287/A10118, 110837, DAMD17-01-1-0729, U01CA116167, DDHK 2004-3124, BBMRI-NL-CP16, R01CA176785, C490/A10124, CA92044, R01CA047147, 70492, P30CA008748, P50CA116201, LVS39420)
David Geffen School of Medicine, University of California, Los Angeles
Medical Research and Materiel Command (DAMD17-01–1-0729)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords: CHEK2 1100delC, germline mutation carriers, breast cancer risk, tumor subtypes, estrogen receptor-positive breast cancer, age-specific risk, cumulative risk, breast cancer risk prediction, Breast Cancer Association Consortium, hereditary breast cancer, odds ratio, heterozygous carriers
MeSH terms: Adult, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms, Female, Heterozygote, Homozygote, Humans, Middle Aged, Receptors, Estrogen, Receptors, Progesterone, Odds Ratio, Case-Control Studies, Sequence Deletion, Risk Assessment, Genetic Predisposition to Disease, Checkpoint Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CH EK 2 *1100delC Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks